References
- Hein HO, Suadicani P, Gyntelberg F. Genetic markers for peptic ulcer. A study of 3387 men aged 54 to 74 years: The Copenhagen Male Study. Scand J Gastroenterol 1997;32: 16–21.
- Archimandritis A, Douvara M, Grigoris S, Tjivras M, Davaris P, Fertakis A. GC and C3 serum groups in peptic ulcer. Hum Hered 1992;42:198–200.
- Arvilommi H. Capacity of complement C3 phenotypes to bind on the mononuclear cells in man. Nature 1974;251:740–1.
- Archimandritis A, Kalogeras D, Chronaki M, Toupadaki N, Souyioultzis S, Apostolopoulos P, et al. Helicobacter pylori (HP) status, complement C3 phenotypes and other factors (socioeconomic-somatometric) in patients with duodenal ulcer (DU). Gut 1998;43(S2):A23.
References
- Archimandritis A, Tzivras M, Fertakis A. C3 phenotypes and peptic ulcer: association of C3 with peptic ulcer but no association of C3 with Helicobacter pylori [letter]. Scand J Gastroenterol 1999;34: 219.
- Lam S-K. Etiology and pathogenesis of peptic ulcer. J Gastroenterol 1994;29 Suppl VII:39–54.
- Suadicani P, Hein HO, Gyntelberg F. Genetic and life-style determinants of peptic ulcer. A study of 3387 men aged 54 to 74 years: The Copenhagen Male Study. Scand J Gastroenterol 1999;34: 12–7.
References
- Wolff K, Stingl G. Pyoderma gangrenosum. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Frank Austen K, editors. Dermatology in general medicine. New York: McGraw-Hill; 1993. p. 1171–82.
- Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991;78:676–8.
- Farmer RG, Easley KA, Rankin GB. Clinical patterns in ulcerative colitis: disease progression, progress and prognosis. Dis Dig Sci 1993;38:1137–46.
- Hanauer SB. Ulcerative colitis. In: Rakel RE, editor. 1998 Conn’s current therapy. Philadelphia: Saunders; 1998. p. 472–9.
- Linn FV, Peppercorn MA. Drug therapy for inflammatory bowel disease. II. Am J Surg 1992;164:178–85.
- Matis WL, Ellis CN, Griffiths CEM, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128:1060–4.
- Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16–9.
- Schmitt EC, Pigatto PD, Boneschi V, Bubola D, Finzi AF. Pyoderma gangrenosum treated with low-dose cyclosporin [letter]. Br J Dermatol 1993;128:230–1.
- Peppercorn MA. Crohn’s disease. In: Rakel RE, editor. 1998 Conn’s current therapy. Philadelphia: Saunders; 1998. p. 479–82.
References
- Quiroga JA, Martn J, Navas S, Carreno V. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 1998;178:247–51.
- Laso FJ, Iglesias MC, Lopez A, Ciudad J, San Miguel JF, Orfao A. Increased interleukin-12 serum levels in chronic alcoholism. J Hepatol 1998;28:771–7.
- Heinzel FP, Hujer AM, Ahmed FN, Rerko RM. In vivo production and function of IL-12p40 homodimers. J Immunol 1997;1:4381–8.
- Kato K, Shimozato O, Hoshi K, Wakimoto H, Hamada H, Yagita H, et al. Local production of the p40 subunit of interleukin-12 suppresses T-helper 1-mediated immune responses and prevents allogenic myoblast rejection. Proc Natl Acad Sci USA 1996;93:9085–9.